CN110698453A

CN110698453A - Pseudorufop-gracilis phenylpropanoids compound and application thereof

Info

Publication number: CN110698453A
Application number: CN201910953807.XA
Authority: CN
Inventors: 何祥久; 王宜海; 肖露; 徐静雯
Original assignee: Guangdong Pharmaceutical University
Current assignee: Guangdong Pharmaceutical University
Priority date: 2019-10-09
Filing date: 2019-10-09
Publication date: 2020-01-17
Also published as: CN111777588B; CN111777588A

Abstract

The invention belongs to the technical field of medicines, and discloses a novel phenylpropanoid compound extracted from pseudorue, which shows an inhibiting effect on inflammation medium NO generated by BV-2 cells induced by LPS through animal pharmacodynamic tests, has an obvious anti-inflammatory effect and NO toxicity on cells, and thus, the pseudorue phenylpropanoid compound can be used for preparing medicines related to inflammation.

Description

Pseudorufop-gracilis phenylpropanoids compound and application thereof

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to a pseudorufa-odorum phenylpropanoid compound and application thereof.

Background

Inflammation is a defense response of living tissues having a vascular system to the production of injury factors. Most diseases are accompanied by inflammation, the inflammation aggravates the occurrence and development of the diseases, and some chronic inflammations even cause tumors, so that the control and treatment of the inflammation are very important.

Natural drugs, especially those derived from plants, have a wide variety of chemical structures and biological activities, and have been a major source of diseases prevention and treatment in humans. Many drugs applied clinically are directly or indirectly derived from natural products, and the natural products can be used not only as semi-synthetic precursors of drugs, but also as templates of chemical synthesis of drugs, thereby providing a new idea for the design of new drugs. Natural products have become one of the main sources for the discovery of new drugs or lead compounds.

Herba seu radix Clerodenri Cyrtophylli (Praxeliscellidoides (Griseb.) R.M.King & H.Robinson.) is a perennial or short-lived perennial herb belonging to the genus Eupatorium (Compositae) and having unique bluish violet clustered flowers. After being crushed, the osmyl grass has a strong smell like cat urine, so the osmyl grass is also called catfish. The pseudo-osmyl grass has strong adaptability and can grow in various climatic regions (such as tropical, tropical rain forest, tropical grassland, subtropical zone, Mediterranean climate and the like).

In fact, the rue-rue grass is regarded as an invasive harmful weed, which rapidly invades the southern china, australia, northern queensland, florida and other global regions in recent years, affects local ecosystems and natural environments, and causes serious economic loss and environmental damage. The osmyl grass usually grows in places such as forests, orchards, wastelands, shrub forests and the like, and has the disadvantages of extremely rapid growth and reproductive capacity, great nutrient consumption in soil, strong destructiveness on soil tiltability, large odor and influence on livestock foraging and crop growth, so that the osmyl grass has adverse effects on agriculture, forestry and animal husbandry in many areas and becomes an invasive malignant weed with destruction potential for local economic development. Because the pseudo-osmyl grass has allelopathic effect and has rejection effect on other herbaceous plants invading the land, thereby causing great threat to the survival and propagation of other biological species and causing the serious reduction of the diversity and the abundance of local organisms.

The main chemical components in the pseudo-rue grass comprise flavonoids, terpenoids, steroids and the like. Researches show that the pseudo-osbeckia has certain antibacterial activity due to the fact that the pseudo-osbeckia contains abundant flavonoid compounds, and chemical substances (such as sesquiterpenes and the like) contained in the pseudo-osbeckia can be used for synthesizing novel botanical pesticides and treating other weeds and plant diseases and insect pests in farmlands. Because the existing research is not thorough enough to research the chemical components of the pseudo-rue, the specific structure and the pharmaceutical function of the chemical components are worthy of further research, development and utilization, thereby providing a new way for the resource utilization of the exotic and malignant weeds.

Disclosure of Invention

The invention aims to confirm chemical components and pharmaceutical effects of pseudorue, provides a pseudorue-rue-grass phenylpropanoids compound and provides application of the pseudorue-rue-ru.

The pseudorufop-p-phenylpropanoids compound provided by the invention has a structural formula shown as the following formula I or formula II:

formula I:formula II:

the invention also provides the application of the pseudorufop-gracilis phenylpropanoids compound, the tautomer thereof and the pharmaceutically acceptable derivative thereof in preparing anti-inflammatory drugs.

Further, the inflammation is any one of neuroinflammation, pneumonia, hepatitis, mastitis, gastritis, bursitis, thromboangiitis obliterans, and myocarditis.

Further, the pharmaceutical dosage form of the anti-inflammatory drug is tablets, powder, granules, capsules, emulsion or syrup.

Furthermore, the pharmaceutical dosage form of the anti-inflammatory drug is injection.

Furthermore, the concentration of the pseudorufop-gracilin compound with the structural formula of formula I and the tautomers and pharmaceutically acceptable derivatives thereof is not lower than 40 mu M.

Further, the pharmaceutically acceptable derivatives of the pseudorufop-gracilin compounds are selected from pharmaceutically acceptable salts, pharmaceutically acceptable esters, acylated compounds, alkylated compounds, active metabolites and optical isomers thereof.

The invention also provides application of the pseudorufop-gracilin compound, the tautomer thereof and the pharmaceutically acceptable derivatives thereof in preparation of medicines for treating Alzheimer's disease.

The invention extracts a novel phenylpropanoid compound from the pseudorue, and animal pharmacodynamic tests show that the novel phenylpropanoid compound has good in-vitro anti-inflammatory activity and can be used for researching and developing new anti-inflammatory drugs.

Drawings

FIG. 1 is a drawing of Compound 1¹H-NMR spectrum;

FIG. 2 is a drawing of Compound 1¹³A C-NMR spectrum;

FIG. 3 is an IR spectrum of Compound 1;

FIG. 4 is a drawing of Compound 2¹H-NMR spectrum;

FIG. 5 is a drawing of Compound 2¹³A C-NMR spectrum;

FIG. 6 is an IR spectrum of Compound 2;

FIG. 7 is a graph showing the inhibitory effect of Compound 1 on protein expression, wherein (A) is a graph showing the protein expression levels of iNOS and COX-2 in BV-2 cells induced by LPS using different concentrations of Compound 1, and (B) is a graph showing the quantification of the protein expression level of (A).

Detailed Description

The technical solution of the present invention is further described below with reference to specific examples.

Example 1

In this example 1,2 compounds were extracted and separated from the herb of rue foetida, and the specific structures of the 2 compounds were confirmed by identifying them, wherein the extraction and separation method comprises the following steps:

(1) cutting 10kg of whole plant of natural dried herba Desmodii Triquetri, and extracting with 75% ethanol at 60 deg.C under reflux for 2 hr for 4 times to obtain concentrated extract (10L).

(2) The extract concentrate was extracted with equal volumes of cyclohexane, chloroform, ethyl acetate and n-butanol successively for 3 times to obtain chloroform layers (74.68 g).

(3) Subjecting chloroform fraction (74.68g) to silica gel column chromatography, performing gradient elution with dichloromethane-methanol (100: 0, 50:1, 20:1, 10:1, 5:1, 3:1, 0: 100; v/v), and collecting dichloromethane-methanol eluate at volume ratio of 50:1 as effective fractions X and Y;

(4) subjecting the effective part X to silica gel column chromatography, performing gradient elution with a cyclohexane-ethyl acetate mixed solution (20: 1-1: 1; v/v), dividing the effective part X into 11 parts, performing reverse phase thin layer analysis, subjecting the 10 th part (the elution part with the volume ratio of cyclohexane to ethyl acetate solution being 1: 1) to medium-low pressure ODS column chromatography, and performing gradient elution with an ethanol water solution (10-100%; v/v); after analysis by reverse phase and silica gel thin layer chromatography, the 5 th fraction (50%; v/v, methanol-water eluate fraction) was subjected to semi-preparative HPLC (40% methanol in water, t;)_R27.0 min) to obtain compound 1.

(5) Subjecting Y to silica gel column chromatography, performing gradient elution with cyclohexane-ethyl acetate (50: 1-1: 1, v/v) to obtain 13 fractions, performing reverse phase thin layer analysis, subjecting the 10 th fraction (elution fraction with cyclohexane and ethyl acetate at volume ratio of 2: 1) to medium-low pressure ODS column chromatography, performing gradient elution with methanol water solution (10% -100%), subjecting the 1 st fraction (10% methanol water elution fraction) to semi-preparative HPLC (40% methanol water, t/v), and subjecting to reverse phase thin layer analysis_R43.6 min) to obtain compound 2.

The above 2 compounds were identified by physicochemical constants and modern spectroscopic means (HR-ESI-MS, 1D NMR, 2D NMR) with the following results:

compound 1:

compound 1 is yellow amorphous powder, is easily soluble in acetone and methanol, exhibits purple fluorescence under ultraviolet 245nm, and changes from yellow to grey blue after heating and developing at 105 deg.C by silica gel thin layer chromatography (10% sulfuric acid-ethanol). An optical rotation of

Process for preparation of Compound 1¹H-NMR、¹³The C-NMR and IR spectra are shown in the figures 1-3 in sequence¹H-NMR and¹³the C-NMR data are shown in Table 1.

HR-ESI-MS (positive) showed M/z 417.1552[ M + H ]]⁺(calcd.for C₂₂H₂₄O₈417.1549), so that the molecular formula is determined to be C₂₂H₂₃O₈。

IR absorption spectrum at 3407cm^-1And 1684cm^-1There is a strong absorption indicating the presence of hydroxyl and aromatic groups.

¹H-NMR(acetone-d₆500MHz), aromatic region delta_H6.98(1H, d, J ═ 1.8Hz) and 6.90(1H, d, J ═ 1.8Hz) were, as a function of the coupling, inferred to be a benzene ring segment in the 1,3,4,5 tetrasubstituted mode; delta_H6.83 the singlet of (2H, s) is deduced to be a fragment of the phenyl ring which is 1,3,4,5 tetrasubstituted and has the same substituents in the 3,5 positions; delta_H7.51(1H, d, J ═ 16.3Hz), 6.96(1H, d, J ═ 16.3Hz) are proton signals on a pair of trans double bonds. High field region delta_H4.96(1H, d, J ═ 8.0Hz) and 4.19(1H, ddd, J ═ 8.0,4.3,2.5Hz) presumably assume the hydrogen signals on the two linked vicinal oxymethylenes, δ_H3.74(1H, dd, J. 12.4, 2.5Hz), 3.52(1H, dd, J. 12.4,4.3Hz) in terms of coupling are presumed to be two hydrogen signals, delta. on the oxymethylene group attached to the above-mentioned methine group_H3.86(3H, s) and 3.85(6H, s) are hydrogen signals of three methoxy groups on benzene ring, delta_H2.29(3H, s) is the hydrogen signal for one methyl group.

¹³C-NMR(acetone-d₆126MHz) spectrum gives a total of 22 carbon signals. Low field region delta_C197.8 carbon signal presumably for one ketocarbonyl group. Aromatic region gives a 14 carbon signal, removed¹H-NMR suggests 12 carbons on two aromatic rings, the remaining two carbon signals being at delta_C143.9, 126.5, two carbon signals on the double bond. At delta_C79.3, 77.7, 61.7 are the carbon signals for the three oxoalkyl radicals, delta_C56.8, 56.4 are the carbon signals of the three methoxy groups on the aromatic ring, delta_C27.44 is a methyl carbon signal. In combination with the hydrogen spectrum, the parent nucleus of the compound is presumed to be 3 ', 7 epoxy-8, 4' -oxyneolignan compound. In HMBC, δ_H2.29(H-10') and δ_C197.8(C-9'), 126.5(C-8') are remotely related, it can be determined that the methyl group is attached to the ketocarbonyl group and that the ketocarbonyl group is attached to the double bond. Delta_H7.51(H-7') and δ_C197.8(C-9'), 127.8(C-1'), 126.5(C-8'), 111.2(C-2') are remotely related and the double bond is determined to be attached to C-1. Delta_H4.96(H-7) and δ_C106.4(C-2,6), 79.3(C-8), 61.7(C-9) remote correlation, inferring C-1' from CH (O) CH₂The OH fragment is C-7 linked. Analysis of H-7 and H-8 by NOESY Spectroscopy No NOE Effect exists and the coupling constants of H-7 'and H-8' (J)_7,88.0Hz), the compound can be judged to be in the threo configuration. In circular dichroism chromatogram, positive Cotton effect appears at 240nm, and negative Cotton effect appears at 280nm, so that the absolute configuration of the compound is 7S and 8S. By passing¹H-NMR、¹³C-NMR (DEPT), HSQC, HMBC, and¹H-¹the carbon and hydrogen signals of the compound can be comprehensively attributed by combining an H COSY spectrum with the literature.

Based on the above information, compound 1 can be inferred to be a phenylpropanoid compound, and is specifically identified as 4- [ (3S) - (4-hydroxy-3, 5-dimethoxy-phenyl) - (2S) -hydroxymethy-8-methoxy-2, 3-dihydroxy- [1,4] dioxin-6-yl ] - (3E) -buten-2-one, namely (7S,8S,7 'E) -4-hydroxy-3, 5, 5' -trimethoxy-3 ', 7-epoxy-8, 4' -oxoneolignan-7 '-en-9' -methylketone, with the structural formula:

compound 2:

the compound 2 is colorless paste, and is easily soluble in acetone and methanol. An optical rotation of

Process for preparation of Compound 2¹H-NMR、¹³The C-NMR and IR spectra are shown in the figures 4-6 in sequence¹H-NMR and¹³the C-NMR data are shown in Table 1.

HR-ESI-MS (positive) shows the excimer peak M/z 309.1343[ M + H ]]⁺(calcd.forC₁₆H₂₁O₆309.1338), determining its molecular formula as C₁₆H₂₀O₆。

IR spectrum of 3425cm^-1And 1683cm^-1There is a strong absorption indicating the presence of aromatic groups and hydroxyl groups.

¹H-NMR(600MHz,Acetone-d₆) Middle, aromatic region delta_H7.35(1H, d, J ═ 1.9Hz), 7.14(1H, dd, J ═ 8.2, 1.9Hz) and 6.87(1H, d, J ═ 8.2Hz) were, depending on the coupling, assumed to be a benzene ring segment of the ABX spin system, δ_H7.58 (1H, d, J ═ 15.9Hz), 6.37(1H, d, J ═ 15.9Hz) are the two proton signals on one trans double bond, δ_H4.78(1H, m), 3.86(1H, m) and 3.66(1H, m) are the hydrogen signals, δ, of the three methines with oxygen presumed_H3.93(3H, s) is the hydrogen signal for one methoxy group.

¹³C-NMR(150MHz,Acetone-d₆) In total, 16 carbon signals are given. Delta_C166.9 carbon signals for an ester carbonyl group, in the aromatic region delta_c150.0(C-4 '), 148.8 (C-3'), 127.5(C-1 '), 124.0 (C-6'), 116.0(C-2 ') and 111.3 (C-5') are the 6 carbon signals on the benzene ring, δ_C145.5 and 116.3 are the two carbon signals on the double bond. Delta_c71.4, 70.3 and 8.5 are the carbon signals of the three vicinal oxymethylene radicals, delta_c35.3, 28.0 and 25.7 are the carbon signals of the three methylene groups. Further attribution by HSQC and HMBC mapping, delta_H7.58 (H-7') and δ_c166.9(C-9′)、127.5(C-1′)、124.0(C-6 '), 116.0(C-2 ') and 111.3(C-5 ') are remotely related and it is concluded that the compound is C₆-C₃A phenylpropionic acid compound with a unit of parent nucleus; by delta_H1.97 (H-3a) and δ_c68.5(C-2) correlation, δ_H1.81(H-3b) and δ_c71.4(C-4) correlation, δ_H1.86(H-6b) and δ_c70.3(C-1) correlation, δ_H1.71(H-5a) and δ_c71.4(C-4), 35.3(C-3) and 28.0(C-6) are related and are defined as six-membered ring fragments with three vicinal oxygen radicals substituted in the 1,2,4 positions.

In conclusion, the compound 2 is a phenylpropanoid compound, and can be identified as (E) -3- (4-hydroxy-3-methoxyphenyl) prop-2-enoic acid- (1,2-dihydroxycyclohexyl) -4-ester, namely (E) -3- (4-hydroxy-3-methoxyphenyl) -2-ene-propionic acid- (1, 2-dihydroxy-cyclohexyl) -4-ester, and the structural formula is as follows:

TABLE 1 of Compounds 1 and 2 of the invention¹H-NMR and¹³C-NMR spectroscopic data (acetone-d)₆)

Example 2

This example uses LPS (lipopolysaccharide) to induce BV-2 (mouse microglia) cells to establish an in vitro inflammation model. The cytotoxicity of a sample is tested through MTT, the NO generation amount is determined through Griess, the influence of the compounds 1 and 2 on the release of an inflammation medium NO by BV-2 cells induced by lipopolysaccharide is examined, and an anti-inflammatory drug minocycline is used as a positive control.

1. MTT assay

BV-2 cells induced by LPS were plated in 96-well plates and cultured for 24 h. Setting a sample group, a negative control group and a blank control group, wherein the sample group is to add a test article to be tested into the cell suspension; the negative control group is a pure cell suspension; the blank control group had no cell suspension and no test article added. After further culturing for 24hThe MTT method was used to determine the inhibition rate of the sample on cell proliferation. Each set of experiments was repeated 3 times. The cell proliferation inhibition rate (negative control group OD value average-sample group OD value average)/(negative control group OD value average-blank control group OD value average) × 100%; and calculating the half Inhibitory Concentration (IC) of the tested sample by using Calcusyn software₅₀)。

2. Griess experiment

Inoculating the BV-2 cells induced by LPS into a 96-well plate, culturing for 24h, adding a test sample to be tested, culturing for 24h, sucking 50 mu L of culture solution of each well, adding 50 mu L of LGriess A reagent and 50 mu L of LGriess B reagent, uniformly mixing, and measuring the OD value at 546nm by using an enzyme-labeling instrument. A model control group and a negative control group are additionally arranged, wherein the model control group is BV2 cells induced by LPS, and the negative control group is normal BV-2 cells. Each set of experiments was repeated 3 times. Calculating the inhibition rate of NO generation, wherein the NO inhibition rate is (model control group OD value average value-sample group OD value average value)/(model control group OD value average value-negative control group OD value average value) × 100%, and calculating the half Inhibition Concentration (IC) of the tested sample by Calcusyn software₅₀)。

The results of the above MTT and Griess experiments are shown in table 2.

TABLE 2 inhibitory Effect of Compounds 1 and 2 of the present invention on the release of NO as an inflammatory mediator from BV-2 cells

From the experimental data in table 2, it can be seen that 2 compounds separated from the pseudo-rue-grass all show better inhibition effects on inflammation mediator NO generated by BV-2 cells induced by LPS, especially, the inhibition effect of compound 1 on inflammation mediator NO is most significant, and IC is₅₀27.54 ± 8.08 μ M, the anti-inflammatory effect of which is comparable to the inhibitory effect of the anti-inflammatory drug minocycline. In MTT experiment, 2 compounds show no cytotoxicity to BV-2 mouse neuromicroglia within the concentration range of 0-100 mu M.

3. Western Blot experiment

Cells in exponential growth phase were seeded in 96-well plates, after LPS was added, compound 1(10.0, 20.0, 40.0 μ M) was added at different concentrations, after stimulation, total protein of each group was extracted at the corresponding time points, electrophoresed in 10% polyacrylamide gel, transferred to NC membrane, blocked, incubated, developed with ECL kit and imaged. Each set of experiments was repeated 3 times. As a control, an experiment group containing no LPS and compound 1 and containing LPS but not compound 1 was set.

The results of the experiment are shown in FIG. 7, the abscissa of the protein expression graph of FIG. 7A and the bar graph of FIG. 7B, in order from left to right, indicates the absence of LPS and Compound 1, the presence of LPS but not Compound 1, the presence of LPS and three different concentrations of Compound 1(10.0, 20.0, 40.0. mu.M), "+" indicates the significance of LPS relative to CTL, "#" indicates the significance of phenylpropanoids relative to actin (CAPDH),^###p＜0.001；^**p＜0.01。

as is clear from FIG. 7, Compound 1 has a certain inhibitory effect on the expression of iNOS protein in BV-2 cells induced by LPS, and the inhibitory effect is increased with the increase in the concentration of Compound 1. When the concentration of the compound 1 is 40 mu M, the iNOS protein expression of BV-2 cells induced by LPS can be obviously reduced, which shows that the compound 1 can reduce NO biosynthesis by inhibiting the iNOS expression, and finally shows an anti-inflammatory effect. Meanwhile, it is presumed that the concentration of compound 1 having an anti-inflammatory effect is 40 μ M or more.

The above results show that the pseudorufop-gracilis compound extracted by the invention can inhibit the generation of inflammatory factor NO and the expression of iNOS protein, has good anti-inflammatory effect, and shows that the pseudorufop-gracilis compound extracted by the invention, the tautomer thereof and the pharmaceutically acceptable derivatives thereof (medicinal salts, medicinal esters, acylated compounds, alkylated compounds, active metabolites and optical isomers) have considerable advantages for preparing novel anti-inflammatory drugs and can be used for treating inflammations such as neuroinflammation, pneumonia, hepatitis, mastitis, gastritis, bursitis, thromboangiitis obliterans, myocarditis and the like. When the pseudorufop-gracilis phenylpropanoids compound, the tautomer thereof and the pharmaceutically acceptable derivative thereof are used for preparing the anti-inflammatory drug, the drug can be prepared into oral administration forms such as tablets, powder, granules, capsules, emulsion and syrup, or non-oral administration forms such as injection.

In addition, because the occurrence and the development of the Alzheimer disease medicine are accompanied by inflammation, particularly related to the iNOS protein expression of BV-2 cells, the pseudorufop-gracilin compound, the tautomer thereof and the pharmaceutically acceptable derivatives thereof can also be used for preparing the medicine for treating the Alzheimer disease.

The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Claims

1. Pseudorufop-phenylpropanoids having the structural formula I or II:

formula I:

formula II:

2. the use of pseudorufop-gracilis compounds of claim 1, and tautomers and pharmaceutically acceptable derivatives thereof for the preparation of anti-inflammatory drugs.

3. Use according to claim 2, characterized in that: the inflammation is any one of neuroinflammation, pneumonia, hepatitis, mastitis, gastritis, bursitis, thromboangiitis obliterans and myocarditis.

4. Use according to claim 2, characterized in that: the pharmaceutical dosage form of the anti-inflammatory drug is tablets, powder, granules, capsules, emulsion or syrup.

5. Use according to claim 2, characterized in that: the pharmaceutical dosage form of the anti-inflammatory drug is injection.

6. Use according to claim 2, characterized in that: the effective concentration of the pseudorufop-gracilis compound with the structural formula of formula I, the tautomer and the pharmaceutically acceptable derivative is not lower than 40 mu M.

7. Use according to claim 2, characterized in that: the pharmaceutically acceptable derivatives of the pseudorufop-gracilin compounds are selected from medicinal salts, medicinal esters, acylated compounds, alkylated compounds, active metabolites and optical isomers of the pseudorufop-gracilin compounds.

8. The use of the pseudorufop-gracilis compound of claim 1, its tautomer, and its pharmaceutically acceptable derivatives in the preparation of a medicament for treating alzheimer's disease.